SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Cubist Pharmaceuticals, Inc. Enrolls 1st Patient in Phase 3 CB-5945 Program for the Treatment of Opioid-Induced Constipation